Funders › TX › William and Ella Owens Medical Research Foundation › 2020
Grants paid by William and Ella Owens Medical Research Foundation, tax year 2020
EIN 74-2884415 · San Antonio, TX · Form 990-PF, Part XV · NTEE E05
In tax year 2020, William and Ella Owens Medical Research Foundation (EIN 74-2884415) reported 49 grants paid totaling $5,156,465. Dataset version 2026.09.0, built 2026-09-03.
Every grant, 2020
| Tax year | Recipient | Match | Amount | Type | Purpose | Source filing |
|---|---|---|---|---|---|---|
| 2020 | U of South Florida Fndtn Co Mildred Acevedo-Duncan Tampa, FL | U | $250,000 | paid | DETERMINE IF ICA-1 CAN TREATBRAIN CANCER BY NEUTRALIZINGTHE CARCINOGEN PKC-IOTA | 202123149349100547 |
| 2020 | U T Health - San Antonio (uthsc-Sa) San Antonio, TX | U | $200,000 | paid | RESEARCH TUMOR-INTRINSIC PD-L1SIGNALS TO DEVELOP MEANS TOCONTROL CANCER STEM CELL FORMATION | 202123149349100547 |
| 2020 | Univ of Tennessee Foundation Memphis, TN | U | $150,000 | paid | KIDNEY AND LUNG CANCER TREATMENT BYTARGETING DPITHELIAL-TO-MESENCHYMAL TRANSITION(EMI) ASSOCIATED WITH RAPALOG NON-RESPONSIVENESS | 202123149349100547 |
| 2020 | U Maryland Med Syst Fndtn Baltimore, MD | U | $140,204 | paid | TREATING PANCREATIC CANCER WITHTARGETED HYPERTHERMIA THROUGH FOCUSEDULTRASOUND TO ENHANCE IMMUNOTHERAPY AND RADIOTHERAPY EFFETS | 202123149349100547 |
| 2020 | Univ of Tennessee Foundation Memphis, TN | U | $129,927 | paid | EVALUATION OF AUTOTAXIN INHIBITORS ASNEW CANCER THERAPIES IN PATIENT-DERIVEDORGANOID AND XENOGRAFT MODELS | 202123149349100547 |
| 2020 | Univ of Tennessee Foundation Memphis, TN | U | $126,421 | paid | CHARACTERIZING A NOVEL STAT3INHIBITOR TO TREAT GLIOBLASTOMA (BRAIN CANCER) | 202123149349100547 |
| 2020 | U T Health - San Antonio (uthsc-Sa) San Antonio, TX | U | $100,705 | paid | TARGETING CASPASE-2 FOR AUGMENTINGBONE STRENGTH | 202123149349100547 |
| 2020 | University of Houston Houston, TX | U | $100,000 | paid | DRUGGING THE UNDRUGGABLE:3 DIMENSIONAL (3D) PEPTOIDS TO TARGET MUTANT RAS PROTEINS IN CANCER | 202123149349100547 |
| 2020 | U T Health - San Antonio (uthsc-Sa) San Antonio, TX | U | $100,000 | paid | USE OF LRP1 IN THE NEURAL STEMCELL NICHE TO AID INRECOVERY AFTER STROKE | 202123149349100547 |
| 2020 | U T Health - San Antonio (uthsc-Sa) San Antonio, TX | U | $100,000 | paid | IMPROVE ISCHEMIC STROKE TREATMENT | 202123149349100547 |
| 2020 | U T Health - San Antonio (uthsc-Sa) San Antonio, TX | U | $100,000 | paid | DEVELOP VACCINES TO STIMULATEIMMUNE RESPONSE TO TREAT MELANOMAA VIRULENT SKIN CANCER | 202123149349100547 |
| 2020 | U T Health - San Antonio (uthsc-Sa) San Antonio, TX | U | $100,000 | paid | POTENTIATING SYNAPSE FORMATION AS A NEWTREATMENT FOR BRAIN DISEASES, INCLUDING ALZHEIMER'S | 202123149349100547 |
| 2020 | U T Health - San Antonio (uthsc-Sa) San Antonio, TX | U | $100,000 | paid | USE OF NOTCH INHIBITORS TOTREAT CHRONIC LYMPHOCYTIC LEUKEMIA | 202123149349100547 |
| 2020 | U Oklahoma Health Sci Cen Oklahoma City, OK | U | $100,000 | paid | PANCREATIC CANCER TREATMENT:IMPROVING EFFECTIVENESS OF CHEMOTHERAPYBY USING SHRNA TO LOWER THE ZINC TRANSPORTER ZIP4 | 202123149349100547 |
| 2020 | University of Houston Houston, TX | U | $100,000 | paid | DISCOVERY OF A NEW DRUG THATKILLS CANCER CELLS BY DIRECTACTIVATION OF THE TET2 TUMOR SUPPRESSOR | 202123149349100547 |
| 2020 | U T Health - San Antonio (uthsc-Sa) San Antonio, TX | U | $100,000 | paid | PROTECTING GENOMIC STABILITYRADIATION-INDUCED DAMAGEUSING MOUSE LEUKEMIA AS A MODEL | 202123149349100547 |
| 2020 | U T Health - San Antonio (uthsc-Sa) San Antonio, TX | U | $100,000 | paid | DEVELOP METHODS OF ENHANCING EFFECTIVENESS OF GLUCORTICOIDTREATMENT OF LEUKEMIA (GLUCORTICOIDS ARE SECRET OFCANCER RESISTANCE OF LONG-LIVED NAKED MOLE RAT) | 202123149349100547 |
| 2020 | Univ of Texas at Austin Austin, TX | U | $100,000 | paid | APPLICATION OF PERSONALIZED MEDICINEWITH A NEW THERAPY TARGETINGGLIOBLASTOMA MULTIFORME (BRAIN CANCER TREATMENT) | 202123149349100547 |
| 2020 | U T Health - San Antonio (uthsc-Sa) San Antonio, TX | U | $100,000 | paid | MIR-585-5P AS A NEW THERAPEUTICADJUVANT FOR TREATINGMEDULLOBLASTOMA | 202123149349100547 |
| 2020 | U T Health - San Antonio (uthsc-Sa) San Antonio, TX | U | $100,000 | paid | CHEMO-PERIODIZED EXERCISE TREATMENTTO IMPROVE CHEMOTHERAPYTOLERANCE IN PROSTATE CANCER TREATMENT | 202123149349100547 |
| 2020 | University of Houston Houston, TX | U | $100,000 | paid | TREATING AGGRESSIVE MELANOMA BYATTENUATING MIR-424/-503 (POTENTIALLYTO TREATMENT OF GLIOBLASTOMA BRAIN CANCER)) | 202123149349100547 |
| 2020 | U Conn Health Center Farmington, CT | U | $100,000 | paid | IODINE NANOPARTICLE-ENHANCEDRADIATION TREATMENT COMBINEDCHEMOTHERAPY TO TREAT BRAIN CANCER | 202123149349100547 |
| 2020 | U T Health - San Antonio (uthsc-Sa) San Antonio, TX | U | $100,000 | paid | NEURONAL HYPEREXCITABILITY ANDNOVEL PHARMACOLOGICALTHERAPY AFTER TRAUMATIC BRAIN INJURY | 202123149349100547 |
| 2020 | U T Health - San Antonio (uthsc-Sa) San Antonio, TX | U | $100,000 | paid | USE OF EWS-FLI-1 TO CHANGETUMOR MICROENVIRONMENT TO TREATEWING SARCOMA (BONE CANCER) | 202123149349100547 |
| 2020 | U T Health - San Antonio (uthsc-Sa) San Antonio, TX | U | $100,000 | paid | ANALYSIS OF CANCER-ASSOCIATEDMITOCHONDRIAL GENOMES TO DEVELOPNEW DIAGNOSES AND TREATMENTS | 202123149349100547 |
| 2020 | U T Health - San Antonio (uthsc-Sa) San Antonio, TX | U | $100,000 | paid | FERROPTOSIS AS A THERAPEUTICTARGET FOR ALZHEIMER'S | 202123149349100547 |
| 2020 | U T Health - San Antonio (uthsc-Sa) San Antonio, TX | U | $100,000 | paid | RESEARCH MIR-124,-128, AND -137TO DEVELOP METHODS TO PREVENTBRAIN DEGENERATION | 202123149349100547 |
| 2020 | University of Houston Houston, TX | U | $100,000 | paid | USE OF SMALL LIVER XRECEPTOR MODULATORS TO KILL PANCREATIC CANCER CELLS | 202123149349100547 |
| 2020 | U T Health - San Antonio (uthsc-Sa) San Antonio, TX | U | $100,000 | paid | NEW LIVER CANCER TREATMENTSBASED ON HIGH THROUGHPUTSCREENING | 202123149349100547 |
| 2020 | U T Health - San Antonio (uthsc-Sa) San Antonio, TX | U | $100,000 | paid | EPINGENETIC-MEDIATEDALTERNATIVE SPLICING IN SF3B1-MUTATED CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS | 202123149349100547 |
| 2020 | Tex Biomed Res Institute San Antonio, TX | U | $100,000 | paid | TUMOR-CAUSING MUTATIONS CAUSEDBY THE IMMUNE RESPONSE TOVIRUSES WITHIN OUR DNA | 202123149349100547 |
| 2020 | U T Health - San Antonio (uthsc-Sa) San Antonio, TX | U | $100,000 | paid | MIR-124, -128, AND -137 AS TRIGGERSOF GLIOBLASTOMA(BRAIN CANCER) DEVELOPMENT | 202123149349100547 |
| 2020 | University of Houston Houston, TX | U | $100,000 | paid | KNOCK-OUT OF NUCLEAR HNRNPA2B1WITH CRISPR-CAS 9 TO ENHANCE PRODUCTIONOF ONCOLYTIC HSV IN VITRO | 202123149349100547 |
| 2020 | U T Health - San Antonio (uthsc-Sa) San Antonio, TX | U | $100,000 | paid | DEVELOP NON OPIOD DRUGS TOTREAT PAIN AT THE SOURCE | 202123149349100547 |
| 2020 | The Menninger Clinic Foundation Houston, TX | B | $100,000 | paid | REDUCING SUICIDE WITH A NEWSLEEP TREATMENT FOR INPATIENTPSYCHIATRY (COGNITIVE BEHAVIORAL THERAPY) | 202123149349100547 |
| 2020 | U T Health - San Antonio (uthsc-Sa) San Antonio, TX | U | $99,998 | paid | DEVELOP MEANS TO PREVENTLIVER DAMAGE DURING CANCERIMMUNOTHERAPY | 202123149349100547 |
| 2020 | U T Health - San Antonio (uthsc-Sa) San Antonio, TX | U | $99,975 | paid | EFFECTIVENESS OF COGNITIVEBEHAVIORAL THERAPY COMBINED WITH MEDICATIONSTO TREAT DEPRESSION CAUSED BY STRESS | 202123149349100547 |
| 2020 | Baylor Scott & White-Cen Tex Fndin Temple, TX | U | $99,910 | paid | CD44 AS A THERPEUTIC TARGET FORMETASTATIC MEDULLOBLASTOMA(BRAIN CANCER) | 202123149349100547 |
| 2020 | U T Health - San Antonio (uthsc-Sa) San Antonio, TX | U | $99,800 | paid | TARGETED DELIVERY OF DRUGS TOREPAIR INJURED NERVES TOTREAT COGNITIVE DECLINE | 202123149349100547 |
| 2020 | U T Health - San Antonio (uthsc-Sa) San Antonio, TX | U | $99,604 | paid | INCREASING THE EFFECTIVENESS OF B1 & C3AS A POTENTIAL TREATMENTOF BREAST CANCER AND MYELOMA | 202123149349100547 |
| 2020 | U T Health - San Antonio (uthsc-Sa) San Antonio, TX | U | $99,494 | paid | ANALYZE METHYLENE BLUE,A SAFE DRUG, TO TREAT PARKINSON'SAND AGE-RELATED COGNITIVE DECLINE | 202123149349100547 |
| 2020 | U T Health - San Antonio (uthsc-Sa) San Antonio, TX | U | $98,804 | paid | USING THE SYNTHETIC PROTEOLYTICDT2216 TO TARGET BCL-XL IN LYMPHOMA(OVERCOMING CHEMOTHERAPY RESISTANCE) | 202123149349100547 |
| 2020 | U T Health - San Antonio (uthsc-Sa) San Antonio, TX | U | $97,750 | paid | USE OF PALMATINE TO ENHANCEGEMCITABINE TREATMENT OFPANCREATIC CANCER | 202123149349100547 |
| 2020 | U T Health - San Antonio (uthsc-Sa) San Antonio, TX | U | $95,264 | paid | RESEARCH TREATING ALZHEIMER'SWITH AN ANTIBODY TO REMOVETAU OLIGOMERS | 202123149349100547 |
| 2020 | U Oklahoma Health Sci Cen Oklahoma City, OK | U | $90,000 | paid | DETERMINE WHETHER SILENCING ZIP4ENHANCES THE EFFECTIVENESS OFCHEMOTHERAPY TREATMENT OF BRAIN CANCER | 202123149349100547 |
| 2020 | U T Health - San Antonio (uthsc-Sa) San Antonio, TX | U | $85,000 | paid | ANALYSIS OF CERTAIN TYPES OFOVARIAN CANCER TO DEVELOPRELEVANT TREATMENTS | 202123149349100547 |
| 2020 | Houston Methodist Hospital Foundation Houston, TX | U | $75,000 | paid | PROGNOSTIC VALUE OF SPECIFICITYPROTEINS IN GASTROINTESTINALCANCERS (COLON & PANCREATIC CANCERS) | 202123149349100547 |
| 2020 | U T Health - San Antonio (uthsc-Sa) San Antonio, TX | U | $65,000 | paid | DEVELOP METHOD OF DIAGNOSISOF PANCREATIC CYSTIC LESIONS | 202123149349100547 |
| 2020 | U T Health - San Antonio (uthsc-Sa) San Antonio, TX | U | $53,609 | paid | IDENTIFYING MICRORNA BY TISSUEOF ORIGIN (CANCEROUS ORHEALTHY) FOR EARLY CANCER DIAGNOSIS | 202123149349100547 |
Match tier: A Reported EIN · B Exact name and place · C Strong name match · D Probable name match · U Unresolved. Tiers C and D are inferred, not reported; see how matching works.
Recipient matching for this dataset version has not yet completed its independent precision check. Tier A rows carry the EIN the filer reported; tiers B–D are the matcher's inference and should be read as leads until the check is published on the methodology page.
Derived from IRS Form 990-PF e-file XML. Dataset version 2026.09.0, built 2026-09-03. All years for this funder.
The same organization elsewhere in the program: exempt status and filing health · federal awards · grant guidance · open opportunities.
This is informational only, derived from public data on the dates shown. It is not an eligibility determination, and not legal, tax, or accounting advice. Verify against the official source before relying on it.